In the subgroup analysis (Figure 3), no statistically significant interaction was observed between the HRs for the primary outcome measure associated with the use of MRA and the clinically relevant subgroup factors such as LVEF, age, sex, previous heart failure hospitalization, diabetes, myocardial infarction, AF or AFL, New York Heart Association class, estimated glomerular filtration rate, and use of the antagonists of the renin-angiotensin system and β-blocker (eTable 2 and eTable 3 in the Supplement). Here, REN is linked to heart failure.